Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting

NCT04501952 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04501952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
September 18, 2020
Completion date
May 6, 2021
Enrollment
584 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19